Takayuki Fujita Selected Research

ethylenediamine (ethylenediamine dihydroiodide)

3/2018	Treatment of oral cancer using magnetized paclitaxel.
8/2017	The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
1/2017	Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment.
1/2016	Simultaneous hyperthermia-chemotherapy with controlled drug delivery using single-drug nanoparticles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takayuki Fujita Research Topics

Disease

8	Heart Failure 01/2020 - 03/2015
8	Neoplasms (Cancer) 11/2018 - 09/2011
6	Hyperthermia 11/2018 - 05/2012
6	Chronic Kidney Failure (Chronic Renal Failure) 01/2015 - 01/2002
5	Type 2 Diabetes Mellitus (MODY) 04/2017 - 05/2010
4	Hypertrophy of Masticatory Muscles 05/2016 - 01/2013
4	Hypertrophy 05/2016 - 01/2013
3	Inflammation (Inflammations) 01/2020 - 02/2010
3	Abdominal Aortic Aneurysm 01/2020 - 01/2012
3	Fibrosis (Cirrhosis) 01/2020 - 01/2008
3	Cardiac Arrhythmias (Arrythmia) 01/2019 - 01/2016
3	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2015 - 01/2004
3	Ischemia 01/2014 - 08/2003
3	Chronic Renal Insufficiency 02/2011 - 06/2010
2	Cardiomyopathies (Cardiomyopathy) 01/2019 - 06/2014
2	Mouth Neoplasms (Oral Cancer) 03/2018 - 05/2014
2	Septic Shock (Toxic Shock Syndrome) 01/2018 - 01/2017
2	Melanoma (Melanoma, Malignant) 07/2017 - 01/2014
2	Atherosclerosis 04/2017 - 01/2002
2	Tongue Neoplasms (Tongue Neoplasm) 01/2017 - 01/2016
2	Aortic Aneurysm (Aneurysm, Aortic) 01/2017 - 01/2012
2	Vasculitis (Vasculitides) 01/2017 - 05/2013
2	Muscular Atrophy (Muscle Atrophy) 05/2016 - 01/2015
2	IGA Glomerulonephritis (IGA Nephropathy) 01/2015 - 01/2008
2	Reperfusion Injury 01/2014 - 07/2011
2	Proteinuria 01/2014 - 01/2007
2	Hypoxia (Hypoxemia) 01/2014 - 08/2012
2	Nephrotic Syndrome (Syndrome, Nephrotic) 06/2013 - 01/2009
2	Glomerulonephritis 05/2013 - 06/2011
2	Body Weight (Weight, Body) 08/2012 - 01/2012
2	Diabetic Nephropathies (Diabetic Nephropathy) 04/2012 - 06/2011
2	Lupus Nephritis 02/2012 - 01/2012
2	Peritonitis 06/2010 - 01/2009
2	Hypertension (High Blood Pressure) 05/2010 - 01/2006
2	Diabetes Mellitus 05/2010 - 01/2006
1	Peripheral Arterial Disease 10/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Endotoxemia 01/2018
1	Poisoning 08/2017

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2008
8	CytokinesIBA 01/2020 - 02/2010
6	erythromycin propionate-N-acetylcysteinateIBA 01/2019 - 12/2014
5	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2018 - 08/2003
5	Complement System Proteins (Complement)IBA 01/2014 - 01/2002
4	mu-oxo N,N'- bis(salicylidene)ethylenediamine ironIBA 03/2018 - 01/2016
4	IronIBA 03/2018 - 01/2016
4	ethylenediamine (ethylenediamine dihydroiodide)FDA Link 03/2018 - 01/2016
4	CatecholaminesIBA 01/2018 - 01/2016
4	AdipokinesIBA 04/2017 - 05/2010
4	ClenbuterolIBA 05/2016 - 09/2013
4	Interleukin-18 (Interleukin 18)IBA 01/2015 - 06/2011
4	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2015 - 01/2013
4	Protein Isoforms (Isoforms)IBA 01/2015 - 01/2013
4	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 01/2012 - 01/2002
3	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2019 - 09/2013
3	Pharmaceutical PreparationsIBA 03/2018 - 01/2016
3	Peroxidase (Myeloperoxidase)IBA 01/2017 - 06/2011
3	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2017 - 06/2011
3	interleukin-18 binding proteinIBA 01/2015 - 06/2011
3	Isoproterenol (Isoprenaline)FDA LinkGeneric 12/2014 - 08/2003
3	Antigen-Antibody Complex (Immune Complex)IBA 02/2012 - 08/2003
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 01/2019
2	Vidarabine (Vira-A)FDA Link 01/2018 - 11/2016
2	Histone Deacetylases (Histone Deacetylase)IBA 05/2016 - 12/2014
2	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 05/2016 - 12/2014
2	Cyclic AMP (AMP, Cyclic)IBA 05/2016 - 12/2014
2	Calcium-Calmodulin-Dependent Protein KinasesIBA 05/2016 - 12/2014
2	ferric oxide (iron oxide)IBA 01/2016 - 05/2014
2	Adrenergic Agents (Adrenergic Drugs)IBA 01/2015 - 09/2013
2	GlucocorticoidsIBA 01/2015 - 06/2013
2	EnzymesIBA 01/2015 - 07/2011
2	Peptides (Polypeptides)IBA 01/2014 - 09/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2014 - 01/2005
2	CreatinineIBA 01/2014 - 02/2011
2	benidipineIBA 02/2011 - 09/2010
2	Angiotensin Receptor AntagonistsIBA 02/2011 - 09/2010
2	Biological ProductsIBA 02/2010 - 08/2003
2	Complement Factor H (Factor H)IBA 01/2007 - 01/2004
1	Lipoproteins (Lipoprotein)IBA 10/2020
1	CholesterolIBA 10/2020
1	CelluloseIBA 10/2020
1	LDL Lipoproteins (beta Lipoproteins)IBA 10/2020
1	oxidized low density lipoproteinIBA 10/2020
1	Dextran SulfateIBA 10/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Dinoprostone (PGE2)FDA Link 01/2020
1	artenimol (dihydroartemisinin)IBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 03/2018
1	CollagenIBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2018
1	disalicylaldehyde ethylenediamine (salen)IBA 08/2017
1	AntidotesIBA 08/2017

Therapy/Procedure

12	Therapeutics 10/2020 - 01/2002
7	Drug Therapy (Chemotherapy) 11/2018 - 05/2012
5	Renal Dialysis (Hemodialysis) 01/2015 - 01/2002
2	Induced Hyperthermia (Thermotherapy) 01/2016 - 05/2014
2	Peritoneal Dialysis 06/2010 - 06/2006
1	Blood Component Removal (Apheresis) 10/2020
1	Chelation Therapy (Therapy, Chelation) 08/2017